

## BIOGRAPHICAL SKETCH

NAME Hiroshi Miyamoto		POSITION TITLE Assistant Professor (from July 2009)	
EDUCATION ( <i>Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.</i> )			
INSTITUTION AND LOCATION	DEGREE	YEAR CONFERRED	FIELD OF STUDY
Yokohama City Univ, Yokohama, Japan	M. D.	1988	Medicine
Yokohama City Univ, Yokohama, Japan	Ph. D.	2000	Medicine (Urology)

### A. RESEARCH AND PROFESSIONAL EXPERIENCE:

- 2001-2005: Research Assistant Professor, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York
- 2005-2008: Resident Physician in Anatomic Pathology, Department of Pathology and Laboratory Medicine, University of Rochester Strong Memorial Hospital, Rochester, New York
- 2008-2009: Clinical Fellow in Urological Pathology, Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland
- 2009-July 1 : Assistant Professor, Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York

### B. Publications:

- Miyamoto H**, Iizawa H, Takahashi T, Miura T, Kinoshita Y, Kubota Y, Hosaka M: An effective case of M-VAC therapy for advanced bladder cancer with extramammary Paget's disease. *Acta Urol. Jpn.* **36**: 1459-1462, 1990.
- Miyamoto H**, Moriyama M, Fukushima S: A case of renal pelvic cancer with lung metastasis showing complete remission by MEC (Methotrexate, Etoposide, Cisplatin) therapy. *Clin. Rep.* **25**: 1631-1633, 1991.
- Kubota Y, Shuin T, Misaki H, Yao M, **Miyamoto H**, Uemura H: (Review) Oncogenes in urogenital cancers. *KARKINOS* **4**: 289-299, 1991.
- Miyamoto H**, Moriyama M, Fukushima S: An effective case of combination therapy with interferon and in advanced renal cell carcinoma. *Biotherapy* **5**: 1827-1829, 1991.
- Miyamoto H**, Moriyama M, Fukushima S: Malignant oncocytoma of the kidney. *Jpn. J. Urol. Surg.* **5**: 341-343, 1992.
- Miyamoto H**, Kuwamitsu O, Moriyama M, Sakanishi S, Fujii H, Fukushima S, Sano J, Oaki Y: Bellini duct carcinoma of the kidney. *Urol. Int.* **48**: 460-462, 1992.
- Miyamoto H**, Miura T, Noguchi S, Shuin T, Kubota Y, Hosaka M: A clinical study of 115 patients with testicular tumor. *Acta Urol. Jpn.* **38**: 797-802, 1992.
- Miyamoto H**, Sekiguchi Y, Moriyama M, Fukushima S: Clinical application of tissue adhesive agent (Fibrin glue) in gaping of postoperative wound. *J. New Remedies Clin.* **41**: 1941-1943, 1992.
- Miyamoto H**, Moriyama M, Fukushima S: Clinical application of tissue adhesive agent (Fibrin glue) in the field of Urology - Studies on testicular hydrocele. *Jpn. J. Clin. Urol.* **46**: 749-751, 1992.
- Fukushima S, Moriyama M, **Miyamoto H**, et al.: Clinical studies on Sulbactam/Cefoperazone in Urology. *Jpn. J. Clin. Exp. Med.* **69**: 3709-3714, 1992.
- Fukushima S, Moriyama M, **Miyamoto H**, et al.: Clinical studies on tosufloxacin (TFLX) in Urology. *Acta Urol. Jpn.* **38**: 501-506, 1992.
- Fukushima S, Moriyama M, **Miyamoto H**, et al.: Clinical studies on lomefloxacin (LFLX) for the treatment of acute uncomplicated cystitis. *Nishinohon J. Urol.* **54**: 2295-2301, 1992.
- Moriyama M, Nomura S, **Miyamoto H**, Fukushima S: Clinical trial of the systemic chemotherapy for advanced prostatic cancer patients. *Jpn. J. Cancer Chemother.* **20**: 969-971, 1993.

- Fukushima S, Moriyama M, **Miyamoto H**: Experience with extracorporeal shock wave lithotripsy in children. *Acta Urol. Jpn.* **39**: 507-509, 1993.
- Noguchi S, Kubota Y, Shuin T, **Miyamoto H**, et al.: Clinical observations on bladder cancer - difference in clinical features with age. *Acta Urol. Jpn.* **39**: 1131-1138, 1993.
- Kubota Y, **Miyamoto H**, Shuin T, Kitamura H: (Review) Oncogenes and tumor suppressor genes in human bladder cancer. *Jpn. J. Urol. Surg.* **6**: 495-500, 1993.
- Miyamoto H**, Moriyama M, Fukushima S: Spontaneous peripelvic extravasation: Report of two cases. *Jpn. J. Urol. Surg.* **6**: 565-569, 1993.
- Usuda K, **Miyamoto H**, Hasegawa T, Shimura K: Cryptorchism and chromosomal abnormalities (Edwards, Patau, Lowe syndrome). *Nippon Rinsho Naibunpishokogun* (extra number 1): 888-891, 1993.
- Miyamoto H**, Kubota Y, Shuin T, Torigoe S, Hosaka M, Iwasaki Y, Danenberg K, Danenberg PV: Analyses of p53 gene mutations in primary human bladder cancer. *Oncol. Res.* **5**: 245-249, 1993.
- Miyamoto H**, Moriyama M, Fukushima S, Nakamura N, Kameda Y: Retroperitoneal tumor eleven years after initial treatment of testicular cancer. *Urology* **43**: 116-117, 1994.
- Miyamoto H**, Usuda K: Spontaneous rupture of the hydronephrotic renal parenchyma associated with urinoma in a child. *Acta Urol. Jpn.* **40**: 419-421, 1994.
- Kubota Y, **Miyamoto H**, Uemura H, Fujinami K, Shuin T: (Review) Oncogenes and tumor suppressor genes in human urogenital cancers. *Jpn. J. Clin. Urol.* **48**: 185-194, 1994.
- Kubota Y, Fujinami K, Uemura H, **Miyamoto H**, Dobashi Y, Shuin T, Hosaka M, Iwasaki Y, Kitamura H: Analysis of tumor suppressor genes in human prostate cancer by RNA-SSCP method. *Fundamental Approaches to the Diagnosis and Treatment for Prostate Cancer and BPH* (Imai K/Shimazaki J/Karr JP Eds.), Adenine Press, Tokyo, pp.157-168, 1994.
- Kubota Y, Shuin T, Noguchi S, Ishibashi Y, **Miyamoto H**, Yao M, Hosaka M, Miura T: Prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer. *Region. Cancer Treat.* **7**: 193-196, 1994.
- Miyamoto H**, Shuin T, Torigoe S, Iwasaki Y, Kubota Y: Retinoblastoma gene mutations in primary human bladder cancer. *Br. J. Cancer* **71**: 831-835, 1995.
- Miyamoto H**, Kubota Y, Shuin T, Torigoe S, Dobashi Y, Hosaka M: Expression of transforming growth factor-beta 1 in human bladder cancer. *Cancer* **75**: 2565-2570, 1995.
- Kubota Y, Shuin T, Uemura H, Fujinami K, **Miyamoto H**, Torigoe S, Dobashi Y, Kitamura H, Iwasaki Y, Danenberg K, Danenberg PV: Tumor suppressor gene p53 mutations in human prostate cancer. *Prostate* **27**: 18-24, 1995.
- Kubota Y, **Miyamoto H**, Noguchi S, Shuin T, Kitamura H, Xu H-J, Hu S-X, Benedict WF: The loss of retinoblastoma gene in association with c-myc and transforming growth factor- 1 gene expression in human bladder cancer. *J. Urol.* **154**: 371-375, 1995.
- Miyamoto H**, Kubota Y, Fujinami K, Dobashi Y, Kondo K, Yao M, Shuin T, Hosaka M: Infrequent somatic mutations of the p16 and p15 genes in human bladder cancer: p16 mutations occur only in low-grade and superficial bladder cancers. *Oncol. Res.* **7**: 327-330, 1995.
- Kubota Y, Fujinami K, Uemura H, Dobashi Y, **Miyamoto H**, Iwasaki Y, Kitamura H, Shuin T: Retinoblastoma gene mutations in primary human prostate cancer. *Prostate* **27**: 314-320, 1995.
- Matsuzaki J, Dobashi Y, **Miyamoto H**, Ikeda I, Fujinami K, Shuin T, Kubota Y: DNA polymerase gene mutations in human bladder cancer. *Mol. Carcinogen.* **15**: 38-43, 1996.
- Miyamoto H**, Shuin T, Ikeda I, Hosaka M, Kubota Y: Loss of heterozygosity at the p53, RB, DCC, and APC tumor suppressor gene loci in human bladder cancer. *J. Urol.* **155**: 1444-1447, 1996.
- Miyamoto H**, Kubota Y, Shuin T, Shiozaki H: Bilateral adrenocortical carcinoma showing allelic losses at the p53 and RB gene loci. *Cancer Genet. Cytogenet.* **88**: 181-183, 1996.
- Lin Y, **Miyamoto H**, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y: Telomerase activity in human bladder cancer. *Clin. Cancer Res.* **2**: 929-932, 1996.
- Yeh S, **Miyamoto H**, Chang C: Hydroxyflutamide may not always be a pure antiandrogen. *Lancet* **349**: 852-853, 1997.

- Hayashi H, **Miyamoto H**, Ito T, Kameda Y, Nakamura N, Kubota Y, Kitamura H: Analysis of p21<sup>Waf1/Cip1</sup> expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. *Am. J. Pathol.* **151**: 461-470, 1997.
- Miyamoto H**, Yeh S, Hwang SB, Fujimoto N, Hsiao P, Ting H, Nishimura K, Wang C, Inui S, Uemura H, Kang H, Chang C: "The androgen receptor co-regulator, ARA<sub>70</sub>" in molecular basis of sex hormone receptor function-new targets for intervention (Gronemeyer H/Fuhrmann U/Parczyk K Eds.), Springer, Berlin, pp.43-51, 1998.
- Takeda M, Noguchi K, Masuda M, Yao M, Kinoshita Y, Hosaka M, Shiozaki H, **Miyamoto H**: Comparative study on morning and evening regimens of fleroxacin (FLRX) for the treatment of complicated urinary tract infections. *Nishinohon J. Urol.* **60**: 733-744, 1998.
- Yeh S, **Miyamoto H**, Shima H, Chang C: From estrogen to androgen receptor: A new pathway for sex hormones in prostate. *Proc. Natl. Acad. Sci. USA* **95**: 5527-5532, 1998.
- Miyamoto H**, Yeh S, Wilding G, Chang C: Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. *Proc. Natl. Acad. Sci. USA* **95**: 7379-7384, 1998.
- Yeh S, **Miyamoto H**, Nishimura K, Kang H, Ludlow J, Hsiao P, Wang C, Su C, Chang C: Retinoblastoma, a tumor suppressor, is a coactivator for the androgen receptor in human prostate cancer DU145 cells. *Biochem. Biophys. Res. Commun.* **248**: 361-367, 1998.
- Miyamoto H**, Yeh S, Lardy H, Messing E, Chang C: <sup>5</sup>-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. *Proc. Natl. Acad. Sci. USA* **95**: 11083-11088, 1998.
- Yeh S, Chang H-C, **Miyamoto H**, Takatera H, Rahman M, Kang H-Y, Thin TW, Lin H-K, Chang C: (Review) Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. *Keio J. Med.* **48**: 87-92, 1999.
- Chang H-C, **Miyamoto H**, Marwah P, Lardy H, Yeh S, Huang K-E, Chang C: Suppression of <sup>5</sup>-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells. *Proc. Natl. Acad. Sci. USA* **96**: 11173-11177, 1999.
- Miyamoto H**, Miyagi Y, Ishikawa T, Ichikawa Y, Hosaka M, Kubota Y: DNA polymerase  $\beta$  gene mutation in human breast cancer. *Int. J. Cancer* **83**: 708-709, 1999.
- Yeh S, Kang H-Y, **Miyamoto H**, Nishimura K, Chang H-C, Ting H-J, Rahman M, Lin H-K, Fujimoto N, Hu Y-C, Mizokami A, Huang K-E, Chang C: Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. *Endocrine* **11**: 195-202, 1999.
- Miyamoto H**, Chang C: Antiandrogens fail to block androstenedione-mediated mutated androgen receptor transactivation in human prostate cancer cells. *Int. J. Urol.* **7**: 32-34, 2000.
- Miyamoto H**, Kubota Y, Noguchi S, Takase K, Matsuzaki J, Moriyama M, Takebayashi S, Kitamura H, Hosaka M: c-erbB-2 gene amplification as a prognostic marker in human bladder cancer. *Urology* **55**: 679-683, 2000.
- Miyamoto H**, Rahman M, Takatera H, Kang H-Y, Yeh S, Chang H-C, Nishimura K, Fujimoto N, Chang C: A dominant-negative mutant of androgen receptor coregulator ARA54 inhibits androgen receptor-mediated prostate cancer growth. *J. Biol. Chem.* **277**: 4609-4617, 2002.
- Sampson ER, Yeh S, **Miyamoto H**, Lee DK, Tsai M-Y, Wang X, Hsu C-L, Chang C: "Interaction of cell cycle regulatory proteins with the androgen receptor" in *Steroid Hormones and Cell Cycle Regulation* (Burnstein KL Ed.), Kluwer Academic Publishers, Norwell, Massachusetts, pp.223-238, 2002.
- Miyamoto H**, Marwah P, Marwah A, Lardy H, Chang C: 3 $\beta$ -Acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity. *Proc. Natl. Acad. Sci. USA* **100**: 4440-4444, 2003.
- Rahman MM, **Miyamoto H**, Takatera H, Yeh S, Altuwaijri S, Chang C: Reducing the agonist activity of antiandrogens by a dominant-negative androgen receptor coregulator ARA70 in prostate cancer cells. *J. Biol. Chem.* **278**: 19619-19626, 2003.

- Rahman MM, **Miyamoto H**, Lardy H, Chang C: Inactivation of androgen receptor coregulator ARA55 inhibits androgen receptor activity and agonist effect of antiandrogens in prostate cancer cells. *Proc. Natl. Acad. Sci. USA*, **100**: 5124-5129, 2003.
- Miyoshi Y, Ishiguro H, Uemura H, Fujinami K, **Miyamoto H**, Miyoshi Y, Kitamura H, Kubota Y: Expression of AR associated protein 55 (ARA55) and androgen receptor in prostate cancer. *Prostate* **56**: 280-286, 2003.
- Nishimura K, Ting H-J, Harada Y, Tokizane T, Nonomura N, Kang H-Y, Chang H-C, Yeh S, **Miyamoto H**, Shin M, Aozasa K, Okuyama A, Chang C: Modulation of androgen receptor transactivation by gelsolin: A newly identified androgen receptor coregulator. *Cancer Res.* **63**: 4888-4894, 2003.
- Miyamoto H**, Rahman MM, Chang C: (Prospects) Molecular basis for the antiandrogen withdrawal syndrome. *J. Cell. Biochem.* **91**: 3-12, 2004.
- Rahman M, **Miyamoto H**, Chang C: (Review) Androgen receptor coregulators in prostate cancer: Mechanisms and clinical implications. *Clin. Cancer Res.* **10**: 2208-2219, 2004.
- Miyamoto H**, Messing EM: Early versus late hormonal therapy for prostate cancer. *Curr Urol Rep* **5**: 188-196, 2004.
- Miyamoto H**, Messing EM, Chang C: (Review) Androgen deprivation therapy for prostate cancer: Current status and future prospects. *Prostate* **61**: 332-353, 2004.
- Miyamoto H**, Messing EM, Chang C: Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? *Nature Clin. Prac. Oncol.* **2**: 236-237, 2005.
- Miyamoto H**: "Hormonal therapy for prostate cancer: Clinical and experimental evidence" in Prostate Cancer – Basic Mechanisms and Therapeutic Approaches (Chang C Ed.), pp.1-32, World Scientific, New Jersey, 2005.
- Miyamoto H**, Altuwaijri S, Cai Y, Messing EM, Chang C: Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: Potential therapeutic approaches for prostate cancer. *Molecular Carcinogenesis* **44**: 1-10, 2005.
- Miyamoto H**, Marwah P, Marwah A, Yang Z, Chung C-Y, Altuwaijri S, Chang C, Lardy H: Identification of steroid derivatives that function as potent antiandrogens. *Int. J. Cancer* **117**: 866-872, 2005.
- Marwah P, Marwah A, Lardy HA, **Miyamoto H**, Chang C: C<sub>19</sub>-Steroids as androgen receptor modulators: Design, discovery, and structure-activity relationship of new steroidal androgen receptor antagonists. *Bioorg. Med. Chem.* **14**: 5933-5947, 2006.
- Fujimoto N, **Miyamoto H**, Mizokami A, Harada S, Nomura M, Ueta Y, Sasaguri T, Matsumoto T: Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; A possible mechanism of hormone-resistance of prostate cancer cells. *Cancer Invest.* **25**: 32-37, 2007.
- Yang Z, Chang Y-J, **Miyamoto H**, Ni J, Niu Y, Chen Z, Chen Y-L, Yao JL, di Sant'Agnes PA, Chang C: Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. *Mol. Endocrinol.* **21**: 343-358, 2007.
- Yang Z, Chang Y-J, **Miyamoto H**, Yeh S, Yao JL, di Sant'Agnes PA, Tsai M-Y, Chang C: Suppression of androgen receptor transactivation and prostate cancer cell growth by heterogeneous nuclear ribonucleoprotein A1 via interaction with AR coregulator ARA54. *Endocrinology* **148**: 1340-1349, 2007.
- Yang Z, Chang Y-J, Yu I-C, Yeh S, Wu C-C, **Miyamoto H**, Merry DE, Sobue G, Chen L-M, Chang S-S, Chang C: ASCJ-9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. *Nat. Med.* **13**: 348-353, 2007.
- Miyamoto H**, Yang Z, Chen Y-T, Ishiguro H, Uemura H, Kubota Y, Nagashima Y, Chang Y-J, Hu Y-C, Tsai M-Y, Yeh S, Messing EM, Chang C: Promotion of bladder cancer development and progression by androgen receptor signals. *J. Natl. Cancer Inst.* **99**: 558-568, 2007.
- Miyamoto H**, Molena DA, Schoeniger LO, Xu H: Solitary fibrous tumor of the pancreas: A case report. *Int. J. Surg. Pathol.* **15**: 311-314, 2007.

- Singer EA, Golijanin DJ, **Miyamoto H**, Messing EM: (Review) Androgen deprivation therapy for prostate cancer. *Expert Opin. Pharmacother.* **9**: 211-228, 2008.
- Miyamoto H**, Altuwaijri S, Chang C: "Androgen receptor in prostate cancer progression" in Current Clinical Oncology: Prostate Cancer: Signaling Networks, Genetics, and New Treatment Strategies (Pestell RG/Nevalainen MT Eds.), pp.129-146, Humana Press, Totowa, New Jersey, 2008.
- Johnson AM, O'Connell MJ, **Miyamoto H**, Huang J, Yao JL, Messing EM, Reeder JE: Androgenic dependence of tumor growth in a transgenic mouse model of bladder cancer: A role for thrombospondin-1. *BMC Urol.* **8**: 7, 2008.
- Niu Y, Yeh S, **Miyamoto H**, Li G, Altuwaijri S, Yuan J, Han B, Ma T, Kuo H-C, Chang C: Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. *Cancer Res.* **68**: 7110-7119, 2008.
- Miyamoto H**, Jones CE, Raymond DP, Wandtke JC, Strang JG, Bourne PA, Bonfiglio TA, Xu H: Pulmonary metastases from uterine neoplasms after long tumor-free interval: Four cases and review of literature. *Pathology*, in press.